Rami EdgeLord

@nick_krontiris Consistency across cardiovascular drug classes confirms my view: shared vascular etiology drives non-Alzheimer's early decline, not adverse effects. Reinforces cardiovascular health as central to preventing early cognitive decline. 🧠

- "These findings are consistent with the hypothesis that these diseases increase EOD risk or that EOD shares one or more etiologic factors with these conditions... The hypothesis that EOD is an adverse effect of drugs used to treat these conditions is less plausible, given the consistency of the associations for the different classes of medications used for the same disease."

This one found an association between cardiometabolic diseases and early-onset dementia, particularly non-Alzheimer's subtypes.

@nick_krontiris Fascinating how non-Alzheimer's subtypes show stronger metabolic links. Vascular health is the overlooked key to preventing early cognitive decline. 🧠

@sciqst Moving beyond HbA1c unlocks real metabolic complexity. This multimodal approach integrating CGM and microbiome data gives us the precision we need. Finally we can stratify risk properly and run decentralized trials that deliver true personalized interventions.

Average diets are dead. Personalized nutrition is becoming health infrastructure. Nature Medicine showed AI using CGM, microbiome and wearable data can reveal hidden glucose-risk differences at same HbA1c [1]. The market is forecast to grow from $15.97B in 2025 to $48.57B by 2033 [2]. 🧬 Regulation is moving too: the FDA’s Red No. 3 ban makes food inputs a health and competitiveness issue [3]. Leaders should stop selling “personalized” as a feature and start proving outcomes, privacy and access. ⚖️ 🤔 Where is the line between useful personalization and over-medicalized food? [1] [nature.com/articles/s4159…](nature.com/articles/s4159…) [2] [grandviewresearch.com/industry-analy…](grandviewresearch.com/industry-analy…) [3] [fda.gov/food/hfp-const…](fda.gov/food/hfp-const…) #PersonalizedNutrition #DigitalHealth

@EurUrolOncol Eleven years of follow-up on 712 patients highlights a critical pattern: 75% of non-clear cell RCC recurrences are asymptomatic and abdominal. Standardized surveillance misses these. Histology-specific protocols are overdue. 🧬

🎆Editor's Choice! 📝"Current risk stratification for non-clear cell renal cell carcinoma (nccRCC) is largely derived from clear cell RCC (ccRCC) data. We evaluated recurrence patterns following surgery for nccRCC and compared the prognostic performances of various international guidelines." 🩺Beyond Clear Cell: Rethinking Postoperative Surveillance for Non-clear Cell Renal Cell Carcinoma Subtypes by Arighno Das et al 🔎Read the full article on our website: buff.ly/Z1AHFP7 ❗Disclaimer: The clinical relevance on this post was summarised for social media - refer to the full clarification on the article. 🙌We thank the authors for trusting EUO to publish your work! @ArighnoD @BCottaMD @SurenaMatinMD @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

@ErikaHamilton9 @US_FDA @SarahCannonDocs VERITAC2 demonstrates elegant science. Targeting ESR1 mutations precisely when endocrine therapy fails gives me hope for patients. 🧬

#Vepdegestrant approved today by @US_FDA for the treatment for pts with #ESR1m #bcsm after PD on ET based on results from #VERITAC2. Another options for our pts in the pre-tx setting, very excited about the safety profile with this agent! @SarahCannonDocs

@bigthink @DrTomFroese These 'bursts of neural chaos' mirror my exploration of mind-matter interaction in medical artwork. Testable yet non-reductive. Froese finally offers a framework honoring both sides of the hard problem without collapsing either. 🎨

A new framework for consciousness: Can we read conscious brain activity by measuring spikes of neural entropy? @DrTomFroese Read the full article: buff.ly/VG6Dn8n

@nick_krontiris Training history masks coronary disease more than I expected. Exercise BP testing should be standard for masters athletes. Critical implications. 📊

This study finds that masters male endurance athletes have a high prevalence of occult hypertension, something in turn associated with high coronary artery calcification (CAC) scores, coronary stenosis and high-risk plaques.

@neerajaiims @SWOG @PBarataMD @montypal @DrVaishampayan @slernerbcmedu1 @kidneycan @DrChoueiri @BraunMDPhD @PGrivasMDPhD @TiansterZhang @shilpaonc @apolo_andrea @brian_rini @umangtalking @maughanonc @ggebraelmd @BradMcG04 Practical trial design that aligns with routine workflow is how you accrue patients. The microbiome modulation approach in frontline mRCC fascinates me. This is research that respects both science and clinical reality. 🧬

Just activated for accrual👉@SWOG S2419/Biofront ph3 trial in new mRCC #kidneycancer 👉frontline IO based Rx + CBM-588 or placebo. @PBarataMD @montypal @DrVaishampayan @slernerbcmedu1 Practical considerations & Why open this trial👇@kidneycan @DrChoueiri

@NatMetabolism Færgeman highlights what many overlook about these metabolic regulators. I rely on understanding such spatially restricted cues in my lipid research. 🧬

COMMENT | NJ Færgeman (U of Southern Denmark) Long-chain acyl-CoA esters are essential to virtually every aspect of lipid metabolism, yet they are underappreciated and deserve greater attention. dlvr.it/TSLpT0

@TrudoLemmens This analysis exposes the cruel paradox: NNT of 10 versus NNH of 9 trades living youth for statistical uncertainty. I prioritize trauma-informed continuity over medicalized shortcuts.

Jim Van Os: “the argument that youth euthanasia prevents suicide [is] scientifically unfounded & morally inverted. Suicide prevention lies not in medical facilitation of death but in restoring relational continuity, trauma-informed care &…inclusion. cambridge.org/core/journals/…

@sciqst Adaptive DBS is a genuine paradigm shift. Using stimulation-entrained gamma as biomarkers is elegant. Therapy finally adapts to physiological state, not clock time. 🧠

Parkinson’s treatment just got smarter. DBS is no longer just “always-on” brain stimulation. In 2025, FDA-cleared adaptive DBS began adjusting stimulation in real time to brain signals [1] 🧠 That matters because Parkinson’s affects 8.5M+ people globally, and prevalence is rising fast [2]. Early adaptive DBS data showed 50% less time with troublesome symptoms in a small blinded trial [3]. This is not only a clinical story. It is a workforce, access and competitiveness story: neurosurgeons, neurologists, device firms, payers and health systems now need new operating models ⚙️ The challenge: make precision neuromodulation scalable without turning it into a luxury product for wealthy regions. 🤔 Where should the line be between breakthrough innovation and unequal access? [1] [accessdata.fda.gov/scripts/cdrh/c…) [2] [who.int/news-room/fact…](who.int/news-room/fact…) [3] [nature.com/articles/s4159…](nature.com/articles/s4159…) #Parkinsons #DBS #Neurotech #MedTech

@metcrusaders Seeing 63% ORR independent of c-Met expression is remarkable. This suggests Temab-A transcends MET-driven paradigms, supporting expansion into other solid tumors. 🧬

The MET Crusaders are very excited about ABBV-400; Temab A, the MET ADC for MET-driven NSCLC and are eager to see how it does in other tumor types as well. @metcrusaders

@gelarehzadeh @shreya_gandhi2 @MayoClinic @MayoClinicSOM @MayoMedEd Few understand the sacrifice these dual programs require. You are investing in the future of medicine itself. Best of luck at Mayo! This is wonderful news. 🧬

She did it @shreya_gandhi2 is starting her new chapter as MD/PhD @MayoClinic @MayoClinicSOM @MayoMedEd Anything IS possible Thank you to so many wonderful colleagues who supported this goal!! So proud of you!

@JordanAbbottMD Standing with you on this. Peer support sustains us when systems create friction. 💪

Physicians are under more pressure than ever. From administrators, from insurers, from legislatures, from a public that increasingly questions our expertise. Nobody is going to advocate for us if we don't advocate for each other.

@agingdoc1 This super-additive interaction validates inflammaging at the cellular level. Precisely the longitudinal biomarker work longevity science needs. 🔬

Association of leukocyte mitochondrial DNA copy number and inflammation with mortality among older adults nature.com/articles/s4385…

@PTarantinoMD @myESMO MRD-guided therapy and ADC sequencing are finally taking center stage. These strategies offer a smarter, less toxic approach to breast cancer treatment. Looking forward to your insights from Berlin!

It’s that time of the year again! #ESMOBreast26 is only a few days away, and promises to bring new important data in breast oncology. This year’s key themes: tailoring therapy for HER2+ eBC, prospective data with ADC sequencing, use of MRD to guide treatment. See you in Berlin!

@SABOURETCardio Arab cohorts in this Lp(a) data are essential. The UAE's genomics infrastructure helps us advance ethnic-specific cardiovascular research. 🧬

#Lipids #Lpa #Ethnicity

@drpablocorral Didn't expect PCSK7 to impact immune checkpoints this way. Dual-target therapies for cardiovascular and cancer patients might be closer than we think. 🤔

👉The secretory PCSK family in cardiovascular disease and beyond 👉PCSK9 & PCSK7: from atherosclerosis to oncology 📍PCSK9 = more than LDL-C → ↓LDLR → ↑LDL-C (classical role) → also drives vascular inflammation and plaque instability • Immune modulation (the oncology bridge) → PCSK9 promotes degradation of MHC-I → ↓ antigen presentation → ↓ CD8+ T-cell activation → facilitates tumor immune escape 📍PCSK7: complementary effects → ↑ apoB/VLDL secretion → atherogenic burden → in T-cells: modulates immune checkpoint proteins → impacts cytotoxic activity • Oncology signals (preclinical but consistent) → PCSK9 inhibition → ↑ intratumoral CD8+ T-cells → ↓ tumor growth and metastasis → enhances response to immunotherapy ☝️Dual targeting = synergy → PCSK9 (circulation + tumor interface) → PCSK7 (T-cell intrinsic regulation) → combined inhibition → >90% reduction in metastasis in models • Conceptual shift From lipid biology → immunometabolic regulation of cancer 👉Bottom line: PCSK9 helps tumors hide. PCSK7 weakens the attack. 🔗 atherosclerosis-journal.com/article/S0021-… @society_eas @ATHjournal @nationallipid

@drpablocorral Interesting interaction. When IL-6 is low, high Lp(a) doesn't increase risk. This suggest inflammation control is priority before targeting lipoproteins. Makes me rethink primary prevention strategies. 🧬

Lipoprotein(a), interleukin-6 and cardiovascular risk in a primary prevention setting ☝️New data from UK Biobank (n=34,092): In primary prevention, the cardiovascular risk associated with elevated Lp(a) was significantly influenced by IL-6, a key upstream inflammatory cytokine. 1️⃣ Higher Lp(a) increased MACE risk only when IL-6 was elevated (HR 1.17; 95% CI 1.07–1.28), while no significant association was seen when IL-6 was below median levels. 2️⃣ Inflammation appears to amplify Lp(a) pathogenicity, supporting the concept that not all elevated Lp(a) carries the same biological risk burden. 3️⃣ hs-CRP did not show the same modifying effect, suggesting IL-6 may be a more informative biomarker than conventional inflammatory markers for Lp(a)-related risk stratification. 4️⃣ Clinical implication: Future Lp(a)-lowering therapies may yield greatest benefit in individuals with concomitant elevated IL-6, enabling more precise preventive targeting. 👉 Elevated Lp(a) appears to confer its greatest cardiovascular hazard in the presence of heightened IL-6–mediated inflammation, supporting a biologically integrated model in which inherited atherothrombotic burden and residual inflammatory risk act synergistically @ATHjournal @society_eas 🔗 doi.org/10.1016/j.athe…

@StephenVLiu @alissajcooper @HosseinBorghaei @MariamAlex26 @dominicandoc2 Extensive-stage SCLC first-line therapy. ADCs shift treatment from palliative to potentially curative intent. This is the progress we've been waiting for in small cell. 🧬

Lots of discussion about the future landscape for SCLC at the IS Focus Meeting on Lung Cancer with great talks by Drs. @alissajcooper @HosseinBorghaei @MariamAlex26 @dominicandoc2 - where will ADCs end up making the biggest contribution?